Trevi Therapeutics, Inc. Stock
Trevi Therapeutics, Inc. Stock price
Key metrics
| Market capitalization | $725.59m |
| Enterprise Value | $622.33m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 6.15 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-50.00m |
| Free Cash Flow (TTM) Free Cash Flow | $-41.00m |
| Cash position | $103.26m |
Is Trevi Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.
Trevi Therapeutics, Inc. Stock Analysis
Analyst Opinions
10 Analysts have issued a Trevi Therapeutics, Inc. forecast:
Analyst Opinions
10 Analysts have issued a Trevi Therapeutics, Inc. forecast:
Financial data from Trevi Therapeutics, Inc.
| Mar '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -50 -50 |
30%
30%
|
EBIT (Operating Income) EBIT | -50 -50 |
30%
30%
|
| Net Profit | -46 -46 |
37%
37%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Trevi Therapeutics, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Trevi Therapeutics, Inc. Stock News
Company Profile
Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.
| Head office | United States |
| CEO | Jennifer Good |
| Employees | 26 |
| Founded | 2011 |
| Website | www.trevitherapeutics.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
